Targeted therapies in the treatment of advanced/metastatic NSCLC

This publication has 107 references indexed in Scilit:

• Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
  British Journal of Cancer, 2008
• Somatic mutations affect key pathways in lung adenocarcinoma
  Nature, 2008
• Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
  The Lancet Oncology, 2008
• MET as a target for treatment of chest tumors
  Lung Cancer, 2008
• A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
  British Journal of Cancer, 2007
• Epidermal growth factor receptor mutations in lung cancer
  Nature Reviews Cancer, 2007
• Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
  British Journal of Cancer, 2007
• A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
  British Journal of Cancer, 2006
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
  The Lancet, 2005
• ERBB receptors and cancer: the complexity of targeted inhibitors
  Nature Reviews Cancer, 2005